Johns Hopkins Diabetes Guide →Management →Type 1 Diabetes
Immunomodulating Therapies in Type 1 Diabetes
Immunomodulating Therapies in Type 1 Diabetes is a topic covered in the Johns Hopkins Diabetes Guide.
To view the entire topic, please sign in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
DEFINITION
- Type 1 diabetes mellitus (T1DM) is an autoimmune disease.
- Destruction of insulin producing beta-cells by T cells renders patients insulin-deficient.
- Exogenous insulin is therefore required for T1DM management of hyperglycemia and to prevent ketoacidosis[19].
- Several immunomodulating therapies have been investigated in research studies over the last decades with the goal of preventing, postponing or reversing the onset of T1DM by slowing or stopping the immune-mediated destruction of beta-cells.
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: September 4, 2017
Citation
TY - ELEC
T1 - Immunomodulating Therapies in Type 1 Diabetes
ID - 547160
A1 - Quartuccio,Michael,M.D.
AU - Lee,Clare,M.D., MHS
AU - Donner,Thomas,M.D.
Y1 - 2017/09/04/
PB - Johns Hopkins Diabetes Guide
UR - https://www.unboundmedicine.com/medline/view/Johns_Hopkins_Diabetes_Guide/547160/all/Immunomodulating_Therapies_in_Type_1_Diabetes
ER -